Search

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Jonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@

Disparity in Mortality From Rheumatic Heart Disease in Indigenous Australians

Indigenous Australians are much more likely to die from Rheumatic Heart Disease than other Australians.

Initiating an undiagnosed diseases program in the Western Australian public health system

We describe the initiation and summary outcomes of a public health system approach for complex undiagnosed patients- the Undiagnosed Diseases Program - WA

Clinical development strategy for a candidate group A streptococcal vaccine

This review outlines a clinical development strategy detailing the phases of development required for registration of a candidate Group A streptococci vaccin

A Comprehensive Needs Assessment Tool for Planning Rheumatic Heart Disease Control Programs in Limited Resource Settings

RHD is an important cause of disability and death in low- and middle-income countries.

Echocardiographic screening for rheumatic heart disease in indigenous Australian children: A cost-utility analysis

Echocardiographic screening for rheumatic heart disease is cost-effective in our context

Rheumatic Heart Disease Severity, Progression and Outcomes: A Multi‐State Model

The prognosis of young Indigenous Australians diagnosed with severe RHD is bleak; interventions must focus on earlier detection and treatment

Rheumatic heart disease across the Western Pacific: not just a Pacific Island problem

We aimed to review RHD burden in Western Pacific Region outside Oceania to identify countries with high RHD burden

Pacific Rheumatic Heart Disease (RHD) Program

The goal of the program is to establish the foundations of an effective, sustainable and equitable response to RHD in the Pacific.

Pharmacokinetics of intramuscular versus subcutaneous administration of Benzathine Penicillin G

Benzathine penicillin G (BPG) has been in use since the 1950s for treatment of skin infections, bacterial pharyngitis, syphilis and prevention of recurrent episodes of acute rheumatic fever (ARF)